Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of vasculitis that often goes unrecognized or misdiagnosed. Patients with EGPA go an average of 4 years between initial symptom onset and diagnosis. Clinicians fail to recognize early, non-specific symptoms of EGPA, delaying treatment that could prevent eosinophil-mediated organ damage. Patients with EGPA are frequently treated with corticosteroids which can result in adverse events that compound the impact of the disease. Newer treatments targeting IL-5 and eosinophil activity may allow for corticosteroid tapering or discontinuation and improvement in patient quality of life. Clinicians should utilize shared decision making to develop treatment plans that prioritize patient-centered goals for managing disease symptoms and minimizing medication toxicity.
Dr. Jennifer Gordon was diagnosed with EGPA in 2014 and is the Vasculitis Patient Powered Research Network (VPPRN) Co-Principal Investigator and co-Lead Patient-Partner in the EGPA Registry. During this 30-minute CMEO Snack, Dr. Gordon will join Dr. Michael Wechsler, a national expert in EGPA. They will discuss how EGPA impacts patient quality of life and how clinicians can better detect and manage hidden symptoms of disease. Patient perspectives on delayed diagnosis, disease impact on their daily functioning, treatment options, and chronic steroid use will be included in the discussion.
At the end of this CME/CE activity, participants should be able to assess how EGPA and associated conditions impact patient QoL.
This educational activity is supported by an educational grant from GSK.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in rheumatology, allergy/immunology, pulmonology, nephrologist, internal medicine, and primary care medicine.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Wechsler reports the following financial relationships: Advisory Board/Consultant: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Cerecor Inc.; Cohero Health, Inc.; CytoReason LTD; Eli Lilly and Company; Equillium Bio; GSK; Incyte; Kinaset Therapeutics; Novartis Pharmaceuticals Corporation; Om Pharma; Phylaxis Bioscience, LLC; PULMATRiX, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Restorbio; Roche/Genentech, Inc.; Sanofi/Genzyme.; Sentien Biotechnologies, Inc.; Sound Biologics; Tetherex Pharmaceuticals; Teva Pharmaceuticals USA, Inc.; and Upstream Bio. Research Support: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi/Genzyme. Speakers Bureau: AstraZeneca; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi.
Dr. Gordon reports the following financial relationships: Consultant/Employee/Stock Options: Excision BioTherapeutics, a biotech start-up company developing gene editing technology for the treatment of infectious disease. This relationship is unrelated to this CE activity.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.